Rezolute, Inc. (NASDAQ:RZLT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.3750.

RZLT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of Rezolute in a research report on Thursday, July 30th. Cantor Fitzgerald reissued a “neutral” rating on shares of Rezolute in a research report on Wednesday, June 3rd. Wedbush boosted their price objective on Rezolute from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Citizens Jmp raised Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price for the company in a research report on Wednesday, June 3rd. Finally, Guggenheim upped their price target on Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, June 15th.

Rezolute Stock Up 1.2%

Rezolute stock opened at $4.22 on Friday. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46. The firm has a fifty day moving average of $4.74 and a 200-day moving average of $3.97. The firm has a market capitalization of $406.34 million, a P/E ratio of -5.15 and a beta of 0.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RZLT. Goldman Sachs Group Inc. acquired a new position in shares of Rezolute in the 1st quarter valued at approximately $685,000. JPMorgan Chase & Co. purchased a new position in shares of Rezolute during the 2nd quarter valued at approximately $141,000. Legal & General Group Plc acquired a new stake in shares of Rezolute during the second quarter worth approximately $32,000. Rhumbline Advisers acquired a new stake in shares of Rezolute during the second quarter worth approximately $432,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Rezolute in the second quarter worth $104,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.